Tyme Technologies, Inc.

Informe acción NasdaqCM:TYME

Capitalización de mercado: US$53.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Tyme Technologies Dirección

Dirección controles de criterios 3/4

Información clave

Richie Cunningham

Chief Executive Officer (CEO)

US$1.3m

Compensación total

Porcentaje del salario del CEO41.97%
Permanencia del CEO1.8yrs
Participación del CEOn/a
Permanencia media de la dirección2.7yrs
Promedio de permanencia en la Junta Directiva6.1yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Sep 15

Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger

Shareholders of Syros Pharmaceuticals (NASDAQ:SYRS) and Tyme Technologies (NASDAQ:TYME) on Thursday voted in favor of the merger between the two biotech companies. SYRS and TYME stock gained more than 20% each in aftermarket trading - SYRS +22% and TYME +24%. Both SYRS and TYME held special stockholder meetings to vote on the merger, the companies said in a statement. SYRS shareholders also voted in favor of the company's concurrent private investment in public equity (PIPE) financing. The closing of the merger and the PIPE financing are anticipated to take place on or around Sept. 16. Post the closing of the merger, the combined company will trade on the Nasdaq under the ticker symbol "SYRS". SYRS also announced a 1-for-10 reverse stock split, with the stock to begin trading on a split-adjusted basis on the Nasdaq on Sept. 19.
Artículo de análisis • Aug 05

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 05

TYME stock surges on merger agreement and Syros Pharmaceuticals

Development stage biotech firms Syros Pharmaceuticals (SYRS) and Tyme Technologies (NASDAQ:TYME) announced on Tuesday that the companies entered into a definitive merger agreement following which Syros (SYRS) will acquire Tyme (TYME). Tyme (TYME) has added ~23% in the pre-market so far while Syros (SYRS) is trading ~6% higher. Per the terms, Syros (SYRS) will issue ~74.3M shares of its common stock to TYME investors and TYME stockholders are entitled to nearly 0.4312 shares of Syros (SYRS) common stock for each TYME stock they hold. The deal is worth about $60M net of wind-down and transaction expenses. Following the merger, the combined entity will be led by Syros’ existing management team and trade on Nasdaq under the ticker symbol “SYRS.” Separately, Syros (SYRS) disclosed an oversubscribed $130M financing of private investment in public equity (PIPE) to purchase a total of up to 138.1M additional shares of common stock at $0.94 apiece. In addition, Syros (SYRS) also announced an amendment to its senior secured loan facility with Oxford Finance LLC. The terms include one year extension to the interest-only payment period and maturity dates subject to conditions revising them to March 1, 2024, and February 1, 2026, respectively. The transactions are expected to close in H2 2022.
Seeking Alpha • May 26

Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives

Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives. Board seems to be leaning towards a sale of the company.
Artículo de análisis • Mar 19

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 07

Tyme Technologies Offers Incredible Risk-Reward

Tyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank. The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices. I review some of the company’s updates and point out a few bullish highlights for investors. In addition, I discuss some of my lingering downside risks for TYME. I update investors on my strategy for managing my TYME position and how I intend to take advantage of the sell-off.
Artículo de análisis • Nov 19

Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 27

Tyme Technologies: The Market Missed The Bullish Memo

Tyme Technologies recently made some big moves following a strategic review. I believe the market has missed the bullish memo about these changes. I review some of these significant changes and provide a bullish memo for investors. In addition, I discuss how these changes have addressed my downside concerns. The recent sell-off provided me with an opportunity to load up near the 52-week lows. I update investors on my strategy for managing my TYME position.
Artículo de análisis • Jul 19

We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Mar 26

Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Artículo de análisis • Feb 19

Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?

Investors may wish to note that an insider of Tyme Technologies, Inc. , Michael Demurjian, recently netted US$55k from...
Artículo de análisis • Feb 02

Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?

A look at the shareholders of Tyme Technologies, Inc. ( NASDAQ:TYME ) can tell us which group is most powerful...
Artículo de análisis • Dec 16

Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?

We wouldn't blame Tyme Technologies, Inc. ( NASDAQ:TYME ) shareholders if they were a little worried about the fact...
Artículo de análisis • Dec 09

Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Richie Cunningham en comparación con los beneficios de Tyme Technologies?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2022n/an/a

-US$24m

Mar 31 2022US$1mUS$564k

-US$24m

Dec 31 2021n/an/a

-US$24m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021US$2mUS$194k

-US$29m

Compensación vs. Mercado: La compensación total de Richie($USD1.34M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD622.00K).

Compensación vs. Ingresos: La compensación de Richie ha sido consistente con los resultados de la empresa en el último año.

CEO

Richie Cunningham (51 yo)

1.8yrs
Permanencia
US$1,344,080
Compensación

Mr. Richard Cunningham, also known as Richie, serves as Chief Executive Officer and Director at Tyme Technologies, Inc. since November 23, 2020. Mr. Cunningham had been the Chief Executive Officer and Pres...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Richard Cunningham
CEO & Director1.8yrsUS$1.34msin datos
Steven Hoffman
Co-Founder & Director9.2yrsUS$2.60m11.63%
$ 6.2m
Frank Porfido
Chief Financial Officer1.3yrsUS$1.29m0.0058%
$ 3.1k
James Biehl
Chief Legal Officer & Secretary4yrsUS$1.19m0.061%
$ 32.7k
Jonathan Eckard
Chief Business Officer3.5yrsUS$858.79ksin datos
Jan Van Tornout
Acting Chief Medical Officer1.4yrssin datos0.0057%
$ 3.1k
2.7yrs
Permanencia media
58yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de TYME se considera experimentado (2.7 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Richard Cunningham
CEO & Director1.8yrsUS$1.34msin datos
Steven Hoffman
Co-Founder & Director7.5yrsUS$2.60m11.63%
$ 6.2m
Timothy Tyson
Independent Director7.5yrsUS$138.73k0.0034%
$ 1.8k
Donald DeGolyer
Independent Director4.3yrsUS$146.99ksin datos
Douglas Michels
Independent Chairman3.9yrsUS$166.34k0.064%
$ 34.2k
David Carberry
Independent Director5.5yrsUS$148.24k0.058%
$ 31.1k
Gerald Sokol
Independent Director & Member of Medical Advisory Board7.5yrsUS$122.87k0.0034%
$ 1.8k
Suresh Chari
Member of Medical Advisory Board6.7yrssin datossin datos
Paul Oberstein
Member of Medical Advisory Boardno datasin datossin datos
Marcus Noel
Member of Medical Advisory Boardno datasin datossin datos
Allyson Ocean
Member of Medical Advisory Boardno datasin datossin datos
Vincent Picozzi
Member of Medical Advisory Boardno datasin datossin datos
6.1yrs
Permanencia media
65yo
Promedio de edad

Junta con experiencia: La junta directiva de TYME se considera experimentada (6.1 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2022/09/16 12:39
Precio de las acciones al final del día2022/09/16 00:00
Beneficios2022/06/30
Ingresos anuales2022/03/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Tyme Technologies, Inc. está cubierta por 3 analistas. de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Arlinda LeeCanaccord Genuity
Joshua SchimmerEvercore ISI
Swayampakula RamakanthH.C. Wainwright & Co.